ReviewCurrent opinion in allergy and clinical immunology2026
Skin pain in pediatric atopic dermatitis: mechanisms and management.
Review in Current opinion in allergy and clinical immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The use of detergents, moisturizers and the experience with therapeutic education among Italian pediatric patients with atopic dermatitis.Italian journal of pediatrics · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewWhile itch is the hallmark symptom of atopic dermatitis (AD), skin pain is increasingly recognized as a common and burdensome symptom even in the pediatric population. Despite its prevalence, pain remains underassessed and undertreated in children with AD. This review aims to synthesize current knowledge on the prevalence, pathophysiology, clinical relevance, and management strategies of skin pain in children with AD. RECENT
findingsSkin pain affects up to 50% of children with AD and is associated with increased disease severity, impaired sleep, reduced quality of life, and higher rates of school absenteeism. Despite its significant impact, few studies have designed pain as a primary outcome, and validated assessment tools for young children are still lacking. Pathophysiological mechanisms involve barrier disruption, neurogenic inflammation, and cytokine-driven sensitization pathways, which may partially diverge from those implicated in itch. Emerging evidence from recent clinical trials suggests that targeted therapies can markedly reduce skin pain, sometimes independently of an improvement in visible lesions. Nonpharmacologic approaches, including emollient therapy, patient education, and psychological support, are also crucial components of a multimodal management strategy. SUMMARY: Skin pain in pediatric AD remains an underrecognized but clinically significant symptom. Incorporating validated, age-appropriate assessment tools and integrated management strategies into clinical practice seems crucial. At the same time, further research should clarify the underlying mechanisms and refine outcome measures to guide the development of targeted therapies for affected children.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.